| Assay ID | Title | Year | Journal | Article |
|---|
| AID551702 | Agonist activity at human PPARalpha in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 10 uM by luciferase reporter gene assay relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320697 | Hypolipidemic effect on diabetic KK-Ay mouse assessed as reduction of plasma triglyceride level at 1 mg/kg/day, po after 4 days | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID551885 | Antihyperlipidemic activity in Sprague-Dawley rat assessed as reduction of serum total cholesterol level at 30 mg/kg, po qd for 14 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320699 | Hypolipidemic effect on diabetic KK-Ay mouse assessed as reduction of plasma VLDL cholesterol level at 1 mg/kg/day, po after 4 days | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348518 | Tmax in Wistar rat at 30 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID551877 | Agonist activity at human PPARdelta in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 10 uM by luciferase reporter gene assay relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320690 | Agonist activity at human PPARgamma expressed in CV1 cells at 10 uM by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348515 | Hypolipidemic activity in high cholesterol fed Sprague-Dawley rat assessed as reduction of total cholesterol level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID551703 | Agonist activity at human PPARgamma in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of transactivation activity at 0.2 uM by luciferase reporter gene assay relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID551887 | Antihyperlipidemic activity in Sprague-Dawley rat assessed as reduction of serum LDL-cholesterol level at 30 mg/kg, po qd for 14 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320688 | Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348520 | Half life in Wistar rat at 30 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID348512 | Hypolipidemic activity in db/db mouse assessed as reduction of triglyceride level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID348516 | Hypolipidemic activity in high cholesterol fed Sprague-Dawley rat assessed as reduction of LDL-C level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID348519 | Cmax in Wistar rat at 30 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID551891 | Cmax in Wistar rat at 30 mg/kg, po | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID371249 | Agonist activity at human PPARalpha transactivation expressed in human HePG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID371251 | Agonist activity at human PPARdelta transactivation expressed in human HePG2 cells up to 1 uM | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID320694 | Agonist activity at mouse PPARalpha expressed in CV1 cells by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID371252 | Selectivity ratio of EC50 for human PPARgamma receptor to human PPARalpha receptor expressed in human HpG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID320691 | Agonist activity at human PPARdelta expressed in CV1 cells at 10 uM by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348521 | AUC (0 to infinity) in Wistar rat at 30 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID320693 | Selectivity for human PPARalpha over human PPARdelta | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348509 | Reduction of triglyceride level in Swiss albino mouse serum at 10 mg/kg/day, po for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID348511 | Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity by transactivation assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID551890 | Tmax in Wistar rat at 30 mg/kg, po | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID348510 | Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity by transactivation assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID551892 | Half life in Wistar rat at 30 mg/kg, po | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320698 | Hypoglycemic effect on diabetic KK-Ay mouse assessed as reduction of plasma glucose level at 1 mg/kg/day, po after 4 days | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID320686 | Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID551883 | Antihyperlipidemic activity in Sprague-Dawley rat assessed as reduction of serum triglycerides level at 30 mg/kg, po qd for 14 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320700 | Hypolipidemic effect on diabetic KK-Ay mouse assessed as increase in plasma HDL cholesterol level at 1 mg/kg/day, po after 4 days | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348513 | Hypoglycemic activity in db/db mouse assessed as reduction of plasma glucose level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID320692 | Selectivity for human PPARalpha over human PPARgamma | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID551889 | Antihyperlipidemic activity in Sprague-Dawley rat assessed as increase of serum HDL-cholesterol level at 30 mg/kg, po qd for 14 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID348517 | Hypolipidemic activity in high cholesterol fed Sprague-Dawley rat assessed as effect on HDL-C level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID320687 | Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID551880 | Antihyperlipidemic activity in db/db mouse assessed as reduction of serum triglycerides level at 30 mg/kg, po qd for 7 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID551893 | AUC (0 to infinity) in Wistar rat at 30 mg/kg, po | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID551881 | Antihyperglycemic activity in db/db mouse assessed as reduction of serum glucose level at 30 mg/kg, po qd for 7 days relative to control | 2011 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. |
| AID320705 | Agonist activity at mouse PPARgamma expressed in CV1 cells at 10 uM by transactivation assay | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID348514 | Hypolipidemic activity in high cholesterol fed Sprague-Dawley rat assessed as reduction of triglyceride level at 3 mg/kg/day for 6 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. |
| AID320696 | Selectivity for mouse PPARalpha over human PPARalpha | 2008 | Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
| Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. |
| AID371250 | Agonist activity at human PPARgamma transactivation expressed in human HePG2 cells | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2004 | The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
| A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lip |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |